Dr. Patricio “Patrick” A. Frias’ is a physician-turned-executive, a path that helped land a new gig as the president and CEO of Rady Children’s Hospital and Health Center.
Inscripta has purchased Solana Biosciences, a San Diego company led by former Illumina veterans that specializes in genomics manufacturing operations.
San Diego-based ResMed has filed a patent infringement petition that is seeking to ban the U.S. import and sale of select breathing masks from New Zealand-based Fisher & Paykel.
BIOTECH: Oral Drug Replaces Shot, Aims for Greater Efficacy
After early years operating on a shoestring budget, Crinetics Pharmaceuticals is flush with cash to pursue ambitious drug development plans.
The U.S. Food and Drug Administration on Aug. 26 declined to approve Waylivra, a drug from Ionis Pharmaceuticals targeting an ultra-rare disease.
Dr. Linda Morrow, COO since 2009, becomes Prosciento's chief medical officer.
Illumina notched approval from the China National Drug Administration to market and sell its MiSeqDx sequencing system to hospitals and other medical institutions throughout the country.
Ajinomoto Althea Inc., the biopharmaceutical contract development and manufacturing company, has opened a 57,000-square-foot manufacturing facility in Sorrento Mesa.
When scouting where to consolidate San Diego operations, Takeda Pharmaceuticals put together a checklist. Most pressing: a plot that could accommodate 300 employees, near research institutions and other life science companies.
Shares of Ionis Pharmaceuticals and spinout Akcea Therapeutics kept falling Tuesday morning after a U.S. Food and Drug Administration division failed to sign off on their drug Waylivra.
The J. Craig Venter Institute filed a motion to dismiss a lawsuit alleging that its CEO, J. Craig Venter, took trade secrets from former employer Human Longevity.
Rakuten Aspyrian hauled in a $150 million Series C round as the company’s lead cancer candidate moves into a final-stage trial.
Businessman, academic and philanthropist Andrew J. Viterbi has given $50 million to UC San Diego to support its ophthalmology programs.
Dthera Sciences’ device intended for Alzheimer’s patients has received a breakthrough designation that will speed regulatory review.
Dr. Christopher Kane will lead the charge to expand primary care access, among other goals, in new roles as dean of clinical affairs for UC San Diego School of Medicine and CEO of UC San Diego Health Physicians.